TNFRSF21 (DR6) is a receptor involved in regulating the immune response that contributes to malignant survival, promoting tumor aggressiveness in lung cancer by increasing ERK/FOXM1 signaling, and cancer stem cell characteristics by promoting CD133 and CD44 mRNA expression [186]. This evidence concerns the gene FOXM1 and lung carcinoma.